XH 001
Alternative Names: XH-001Latest Information Update: 03 May 2024
At a glance
- Originator NeoCura
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Pancreatic cancer
Most Recent Events
- 12 Apr 2024 Preclinical trials in Pancreatic cancer in China (Parenteral)
- 09 Apr 2024 NeoCura plans a clinical trial for Pancreatic cancer (Combination therapy, neoadjuvant therapy) in China (NCT06353646)